Polycystic ovary syndrome: A diagnostic challenge

Infertility and Reproductive Medicine Clinics of North America

Volumn 14, Issue 4, 2003, Pages 497-516

  Lewis, Vivian ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADOTROPIN; LUTEINIZING HORMONE;

ADRENAL TUMOR; AMENORRHEA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ENDOCRINE TUMOR; FAMILY HISTORY; FEMALE; GONADOTROPIN RELEASE; HIRSUTISM; HORMONE DETERMINATION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERTHECOSIS; INSULIN RESISTANCE; MENSTRUATION DISORDER; OBESITY; OVARY DISEASE; OVARY FOLLICLE; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; REAL TIME ECHOGRAPHY; REVIEW;

EID: 0242302622     PISSN: 10479422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.
2. Zawadzki JK, Duniaf A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, et al, editors. Polycystic ovary syndrome: current issues in endocrinology and metabolism, Vol. 4. Boston: Blackwell Scientific; 1992. p. 377-84.
3. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol 1989;31: 87-120.
4. Franks S. Polycystic ovary syndrome [published erratum appears in N Engl J Med 1995;23; 333(21):1435]. N Engl J Med 1995;333:853-61.
5. Franks S. Polycystic ovary syndrome [published erratum appears in N Engl J Med 1995;23; 333(21):1435]. N Engl J Med 1995;333:853-61.
6. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998;27:877-902.
7. Goldzieher JW, Axelrod LR. Clinical and biochemical features of polycystic ovarian disease. Fertil Steril 1963;14:631-53.
8. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol 1989;30:459-70.
9. Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-11.
10. Ferrimen D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
11. Hatch R, Rosenfield RL, Kim MH, et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-30.
12. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 1983; 147:90-101.
13. Grasinger CC, Wild RA, Parker IJ. Vulvar acanthosis nigricans: a marker for insulin resistance in hirsute women. Fertil Steril 1993;59:583-6.
14. Dunaif A, Green G, Phelps RG, et al. Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab 1991;73: 590-5.
15. Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med 1989;87:269-72.
16. Urbanek M, Legro RS, Driscoll DA, et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistattin. Proc Natl Acad Sci USA 1999;96: 8573-8.
17. Seminara SB, Crowley Jr WF. Genetic approaches to unraveling reproductive disorders: examples of bedside to bench research in the genomic era. Endocr Rev 2002;23:382-92.
18. Cooper HE, Spellacy WN, Prem KA, et al. Hereditary factors in Stein Leventhal syndrome. Am J Obstet Gynecol 1968;100:371-87.
19. Legro RS, Kunselman AR, Demers L, et al. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:2134-8.
20. Gharani N, Waterworth DM, Williamson R, et al. 5′ Polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J Clin Endocrinol Metab 1996;81:4174.
21. Gharani N, Waterworth DM, Batty S, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397-402.
22. Calvo RM, Asuncion M, Telleria D, et al. Screening for mutations in the steroidogenic acute regulatory protein and steroidogenic factor-1 genes, and in CYP11A and dosage-sensitive sex reversal-adrenal hypoplasia gene on the X chromosome, gene-1 (DAX-1), in hyperandrogenic hirsute women. J Clin Endocrinol Metab 2001;86:1746-9.
23. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:161-5.
24. Mifsud A, Ramirez S, Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab 2000;85:3484-8.
25. Calvo RM, Asuncion M, Telleria D, et al. The role of CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation, in the pathogenesis of hirsutism. J Clin Endocrinol Metab 2001;86:1746-9.
26. Yildiz BO, Yarali H, Oguz H, et al. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2031-6.
27. Sir-Petermann T, Angel B, Maliqueo M, et al. Prevalence of type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia 2002;45: 959-65.
28. Wajchenberg BL, Achando SS, Okada H, et al. Determination of the source(s) of androgen overproduction in hirsutism associated with polycystic ovary syndrome by simultaneous adrenal and ovarian venous catheterization: comparison with the dexamethasone suppression test. J Clin Endocrinol Metab 1986;63:1204-10.
29. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-111.
30. Wild RA, Umstot ES, Andersen RN, et al. Androgen parameters and their correlation with body weight in 138 women thought to have hyperandrogenism. Am J Obstet Gynecol 1983;146: 602-6.
31. Robinson S, Rodin DA, Deacon A, et al. Which hormone tests for the diagnosis of polycystic ovary syndrome? Br J Obstet Gynaecol 1992;99:232-8.
32. Boots LR, Potter S, Potter D, et al. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertil Steril 1998;69: 286-92.
33. Wheeler MJ, Lowy C. Warning on serum testosterone measurement [letter]. Lancet 1987;2: 514-5.
34. Wheeler MJ, Shaikh M, Jennings RD. An evaluation of 13 commercial kits for the measurement of testosterone in serum and plasma. Ann Clin Biochem 1986;23:303-9.
35. Kiddy DS, Hamilton-Fairley D, Seppala M, et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor I. Clin Endocrinol 1989;31:757-63.
36. Derksen J, Nagesser SK, Meinders AE, et al. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994;331:968-73.
37. Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992;167:1807-12.
38. Allen SE, Potter HD, Azziz R. Prevalence of hyperandrogenemia among nonhirsute oligo-ovulatory women. Fertil Steril 1997;67:569-72.
39. Azziz R, Rittmaster RS, Fox LM, et al. Role of the ovary in the adrenal androgen excess of hyperandrogenic women. Fertil Steril 1998;69:851-9.
40. Ehrmann DA, Rosenfield RL, Barnes RB, et al. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992;327:157-62.
41. Gilling-Smith C, Willis DS, Franks S. Oestradiol feedback stimulation of androgen biosynthesis by human theca cells. Hum Reprod 1997;2:1621-8.
42. Arroyo A, Laughlin GA, Morales AJ, et al. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 1997;82:3728-33.
43. Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970;30:435-42.
44. Ropelato MG, Garcia-Rudaz MC, Castro-Fernandez C, et al. A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both basal and pulsatile LH in adolescents with polycystic ovarian syndrome. J Clin Endocrinol Metab 1999;84: 4629-36.
45. Chang RJ, Laufer LR, Meldrum DR, et al. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 1983;56:897-903.
46. Hayes FJ, Taylor AE, Martin KA, et al. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics. J Clin Endocrinol Metab 1998;83:2343-9.
47. Lockwood GM, Muttukrishna S, Groome NP, et al. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. J Clin Endocrinol Metab 1998;83:1730-5.
48. Fauser BC, Pache TD, Hop WC, et al. The significance of a single serum LH measurement in women with cycle disturbances: discrepancies between immunoreactive and bioactive hormone estimates. Clin Endocrinol 1992;37:445-52.
49. Rebar R, Judd HL, Yen SS, et al. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976;57:1320-9.
50. Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82: 2248-56.
51. Lobo RA, Shoupe D, Chang SP, et al. The control of bioactive luteinizing hormone secretion in women with polycystic ovary syndrome. Am J Obstet Gynecol 1984;48:423-8.
52. Fauser BC, Pache TD, Lamberts SW, et al. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab 1991;73:811-7.
53. van Hooff MH, van der Meer M, Lambalk CB, et al. Variation of luteinizing hormone and androgens in oligomenorrhea and its implications for the study of polycystic ovary syndrome. Hum Reprod 1999;14:1684-9.
54. Bohlke K, Cramer DW, Barbieri RL. Relation of luteinizing hormone levels to body mass index in premenopausal women. Fertil Steril 1998;69:500-4.
55. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83: 2694-8.
56. Cibula D, Skrha J, Hill M, et al. Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:5821-5.
57. Jayagopal V, Kilpatrick ES, Jennings PE, et al. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 2003;88:1528-33.
58. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6.
59. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
60. Legro RS. Polycystic ovary syndrome: current and future treatment paradigms. Am J Obstet Gynecol 1998;179:S101-8.
61. Eden JA, Place J, Carter GD, et al. The diagnosis of polycystic ovaries in subfertile women. Br J Obstet Gynaecol 1989;96:809-15.
62. el Tabbakh GH, Lotfy I, Azab I, et al. Correlation of the ultrasonic appearance of the ovaries in polycystic ovarian disease and the clinical, hormonal, and laparoscopic findings. Am J Obstet Gynecol 1986;154:892-5.
63. Swanson M, Sauerbrei EE, Cooperberg PL. Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound 1981;9:219-22.
64. Adams J, Franks S, Polson DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985;2:1375-9.
65. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986;293:355-9.
66. Buckett WM, Bouzayen R, Watkin KL, et al. Ovarian stromal echogenicity in women with normal and polycystic ovaries. Hum Reprod 1999;14:618-21.
67. Takahashi K, Eda Y, Okada S, et al. Morphological assessment of polycystic ovary using transvaginal ultrasound. Hum Reprod 1993;8:844-9.
68. Kyei-Mensah A, Maconochie N, Zaidi J, et al. Transvaginal three-dimensional ultra sound: reproducibility of ovarian and endometrial volume measurements. Fertil Steril 1996;66: 718-22.
69. Tulandi T, Watkin K, Tan SL. Reproductive performance and three-dimensional ultrasound volume determination of polycystic ovaries following laparoscopic ovarian drilling. Int J Fertil Womens Med 1997;42:436-40.
70. Pache TD, Wladimiroff JW, Hop WC, et al. How to discriminate between normal and polycystic ovaries: transvaginal US study. Radiology 1992;183:421-3.
71. Battaglia C, Artini PG, D'Ambrogio G, et al. The role of color Doppler imaging in the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 1995;172:108-13.
72. Zaidi J, Campbell S, Pittrof R, et al. Ovarian stromal blood flow in women with polycystic ovaries - possible new marker for diagnosis? Hum Reprod 1995;10:1992-6.
73. van Santbrink EJ, Hop WC, Fauser BC. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril 1997;67:452-8.
74. Fox R. Transvaginal ultrasound appearances of the ovary in normal women and hirsute women with oligomenorrhoea. Aust N Z J Obstet Gynaecol 1999;39:63-8.
75. Robert Y, Dubrulle F, Gaillandre L, et al. Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: visual analysis versus computerized quantification. Fertil Steril 1995;64:307-12.
76. Polson DW, Adams J, Wadsworth J, et al. Polycystic ovaries - common finding in normal women. Lancet 1988;1:870-2.
77. Koivunen R, Laatikainen T, Tomas C, et al. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand 1999;78:137-41.
78. Michelmore KF, Balen AH, Dunger DB, et al. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol 1999;51:779-86.
79. Carmina E, Wong L, Chang L, et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 1997;12:905-9.
80. Hague WM, Adams J, Rodda C, et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin Endocrinol 1990;33:501-10.
81. Friedman CI, Schmidt GE, Kim MH, et al. Serum testosterone concentrations in the evaluation of androgen-producing tumors. Am J Obstet Gynecol 1985;153:44-9.
82. Waggoner W, Boots LR, Azziz R. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study. Gynecol Endocrinol 1999;13:394-400.
83. Nagamani M, Lingold JC, Gomez LG, et al. Clinical and hormonal studies in hyperthecosis of the ovaries. Fertil Steril 1981;36:326-32.
84. Meldrum DR, Abraham GE. Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors. Obstet Gynecol 1979;53:36-43.
85. Dunaif A, Hoffman AR, Scully RE, et al. Clinical, biochemical, and ovarian morphologic features in women with acanthosis nigricans and masculinization. Obstet Gynecol 1985;66: 545-52.
86. Yen SSC. Polycystic ovary syndrome. In: Yen SSC, Jaffe RB, Barbieri RL, editors. Reproductive endocrinology: physiology, pathophysiology, and clinical management. 4th edition. Philadelphia: WB Saunders; 1999. p. 436-77.
87. Barth JH, Jenkins M, Belchetz PE. Ovarian hyperthecosis, diabetes and hirsuties in postmenopausal women. Clin Endocrinol 1997;46:123-8.
88. Nagamani M, Osuampke C, Kelver ME. Increased bioactive luteinizing hormone levels and bio/immuno ratio in women with hyperthecosis of the ovaries: possible role of hyperinsulinemia. J Clin Endocrinol Metab 1999;84:1685-9.
89. Nagamani M, Van Dinh T, Kelver ME. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol 1986;154:384-9.
90. Nagamani M, Urban RJ. Increased expression of messenger ribonucleic acid encoding cytochrome P450 cholesterol side-chain cleavage and P450 17-alpha-hydroxylase enzymes in ovarian hyperthecosis. Fertil Steril 1999;71:328-33.
91. Horton R, Hawks D, Lobo R. 3 Alpha, 17 beta-androstanediol glucuronide in plasma: a marker of androgen action in idiopathic hirsutism. J Clin Invest 1982;69:1203-6.
92. Azziz R, Waggoner WT, Ochoa T, et al. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertil Steril 1998;70:274-8.
93. O'Driscoll JB, Mamtora H, Higginson J, et al. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol 1994;41:231-6.
94. Azziz R, Dewailly D, Owerbach D. Nonclassic adrenal hyperplasia: current concepts [clinical review]. J Clin Endocrinol Metab 1994;78:810-5.
95. Moran C, Knochenhauer ES, Azziz R. Non-classic adrenal hyperplasia in hyperandrogenism: a reappraisal. J Endocrinol Invest 1998;21:707-20.
96. Levin JH, Carmina E, Lobo RA. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia? Fertil Steril 1991;56:635-40.
97. Speiser PW, Serrat, J, New MI, et al. Insulin insensitivity in adrenal hyperplasia due to non-classical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992;75:1421-4.
98. Azziz R, Hincapie LA, Knochenhauer ES, et al. Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 1999;72:915-25.
99. Coonrod DV, Rizkallah TH. Virilizing adrenal carcinoma in a woman of reproductive age: a case presentation and literature review. Am J Obstet Gynecol 1995;172:1912-4.
100. Glickman SP, Rosenfield RL, Bergenstal RM, et al. Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women. J Clin Endocrinol Metab 1982;55: 251-7.
101. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol 1999;50:655-9.